Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 1/20 | 0.56 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 13/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813745 | 0.93 | MAPT (0.57) | STK17BSTK17AMAPTBRD4HTT | |
| SCHEMBL3410303 | 0.87 | STK17B (0.49) | STK17BSTK17ABRD4SIRT5LMNA | |
| SCHEMBL29802555 | 0.85 | STK17A (0.72) | STK17BSTK17ABRD4SIRT5 | |
| SCHEMBL3812414 | 0.83 | MAPT (0.44) | STK17BSTK17AMAPTBRD4LMNA | |
| SCHEMBL20278061 | 0.82 | CA12 (0.47) | STK17BSTK17AMAPTBRD4HTT | |
| SCHEMBL8290003 | 0.82 | LMNA (0.64) | STK17BSTK17AMAPTBRD4LMNA | |
| SCHEMBL3815624 | 0.82 | STK17B (0.45) | STK17BSTK17ABRD4SIRT5LMNA | |
| SCHEMBL3815680 | 0.80 | MAPT (0.55) | STK17AMAPTHTTSIRT5LMNA | |
| SCHEMBL3408429 | 0.80 | TXNRD1 (0.47) | STK17BSTK17AMAPTBRD4LMNA | |
| SCHEMBL8041119 | 0.80 | STK17B (0.46) | STK17BSTK17AMAPTBRD4SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615925-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | IPSEN PHARMA (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-7495009-B2 | Imidazopyridine derivatives as melancortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20060173036-A1 | Imidazopyridine derivatives as melanocortin receptor agonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S) (FR) | 2006-08-03 | — | — | US | disclosed |
| EP-1615925-A1 | IMIDAZOPYRIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089951-A1 | IMIDAZOPYRIDINE DERIVATIVES HAVING AN AFFINITY FOR MELANOCORTIN RECEPTORS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173036-A1 | Imidazopyridine derivatives as melanocortin receptor agonists | MC4R, MC1R, MC3R | STK17B 1802/4885STK17A 1557/4885MAPT 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.